|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
ES2969742T3
(es)
|
2012-03-27 |
2024-05-22 |
CureVac SE |
Moléculas artificiales de ácido nucleico para la expresión mejorada de proteínas o péptidos
|
|
US9974845B2
(en)
|
2013-02-22 |
2018-05-22 |
Curevac Ag |
Combination of vaccination and inhibition of the PD-1 pathway
|
|
CN105473157A
(zh)
|
2013-08-21 |
2016-04-06 |
库瑞瓦格股份公司 |
组合疫苗
|
|
KR102354389B1
(ko)
|
2013-08-21 |
2022-01-20 |
큐어백 아게 |
Rna―암호화된 단백질의 발현을 증가시키는 방법
|
|
ES2747762T3
(es)
|
2013-08-21 |
2020-03-11 |
Curevac Ag |
Vacuna contra el virus respiratorio sincitial (RSV)
|
|
CN110195072A
(zh)
|
2013-08-21 |
2019-09-03 |
库瑞瓦格股份公司 |
狂犬病疫苗
|
|
ES2806575T3
(es)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
ARN modificado con propiedades inmunoestimuladoras disminuidas
|
|
JP6584414B2
(ja)
|
2013-12-30 |
2019-10-02 |
キュアバック アーゲー |
人工核酸分子
|
|
AU2014375402B2
(en)
|
2013-12-30 |
2020-10-01 |
CureVac SE |
Artificial nucleic acid molecules
|
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
|
ES2754239T3
(es)
|
2014-03-12 |
2020-04-16 |
Curevac Ag |
Combinación de vacunación y agonistas de OX40
|
|
WO2015149944A2
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Gmbh |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
BR112016026980B1
(pt)
|
2014-06-10 |
2022-05-03 |
Curevac Real Estate Gmbh |
Método para sintetizar uma molécula de rna de uma dada sequência
|
|
HRP20221536T1
(hr)
|
2014-06-25 |
2023-02-17 |
Acuitas Therapeutics Inc. |
Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
|
|
DK4023755T5
(da)
|
2014-12-12 |
2024-07-29 |
CureVac SE |
Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse
|
|
AU2015373404B2
(en)
*
|
2014-12-30 |
2021-09-09 |
CureVac SE |
Artificial nucleic acid molecules
|
|
WO2016165825A1
(en)
|
2015-04-13 |
2016-10-20 |
Curevac Ag |
Method for producing rna compositions
|
|
US10780054B2
(en)
|
2015-04-17 |
2020-09-22 |
Curevac Real Estate Gmbh |
Lyophilization of RNA
|
|
AU2016251687C1
(en)
|
2015-04-22 |
2023-07-27 |
CureVac SE |
RNA containing composition for treatment of tumor diseases
|
|
EP3289083A4
(en)
|
2015-04-27 |
2018-12-19 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
SG11201708867UA
(en)
|
2015-04-30 |
2017-11-29 |
Curevac Ag |
Immobilized poly(n)polymerase
|
|
EP3294885B1
(en)
|
2015-05-08 |
2020-07-01 |
CureVac Real Estate GmbH |
Method for producing rna
|
|
DK3294326T3
(da)
|
2015-05-15 |
2021-05-31 |
Curevac Ag |
Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
|
|
US10517827B2
(en)
|
2015-05-20 |
2019-12-31 |
Curevac Ag |
Dry powder composition comprising long-chain RNA
|
|
US10729654B2
(en)
|
2015-05-20 |
2020-08-04 |
Curevac Ag |
Dry powder composition comprising long-chain RNA
|
|
WO2016193206A1
(en)
|
2015-05-29 |
2016-12-08 |
Curevac Ag |
A method for producing and purifying rna, comprising at least one step of tangential flow filtration
|
|
EP4098743A1
(en)
|
2015-05-29 |
2022-12-07 |
CureVac AG |
Method for adding cap structures to rna using immobilized enzymes
|
|
CA2990202A1
(en)
|
2015-06-29 |
2017-01-05 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2017009376A1
(en)
|
2015-07-13 |
2017-01-19 |
Curevac Ag |
Method of producing rna from circular dna and corresponding template dna
|
|
CN114381470A
(zh)
|
2015-08-28 |
2022-04-22 |
库瑞瓦格股份公司 |
人工核酸分子
|
|
DK3350157T3
(da)
|
2015-09-17 |
2022-02-14 |
Modernatx Inc |
Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
|
|
WO2017059902A1
(en)
*
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
EP3362576A1
(en)
|
2015-10-12 |
2018-08-22 |
CureVac AG |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
DK3362461T3
(da)
|
2015-10-16 |
2022-05-09 |
Modernatx Inc |
Mrna-cap-analoger med modificeret phosphatbinding
|
|
AU2016340183A1
(en)
|
2015-10-16 |
2018-04-19 |
Modernatx, Inc. |
mRNA cap analogs and methods of mRNA capping
|
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
|
MA52645B1
(fr)
|
2015-10-22 |
2022-06-30 |
Modernatx Inc |
Vaccins contre le virus respiratoire
|
|
PT3368507T
(pt)
|
2015-10-28 |
2023-02-07 |
Acuitas Therapeutics Inc |
Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
|
|
US11413346B2
(en)
|
2015-11-09 |
2022-08-16 |
Curevac Ag |
Rotavirus vaccines
|
|
US11684665B2
(en)
|
2015-12-22 |
2023-06-27 |
CureVac SE |
Method for producing RNA molecule compositions
|
|
AU2016377681B2
(en)
|
2015-12-22 |
2021-05-13 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
US11248223B2
(en)
|
2015-12-23 |
2022-02-15 |
Curevac Ag |
Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
WO2017127750A1
(en)
|
2016-01-22 |
2017-07-27 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
MX2018009917A
(es)
|
2016-02-17 |
2019-08-14 |
Curevac Ag |
Vacuna contra el virus del zika.
|
|
US11920174B2
(en)
|
2016-03-03 |
2024-03-05 |
CureVac SE |
RNA analysis by total hydrolysis and quantification of released nucleosides
|
|
US20190167811A1
(en)
|
2016-04-13 |
2019-06-06 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
|
EP4487869A3
(en)
*
|
2016-04-22 |
2025-07-30 |
CureVac SE |
Rna encoding a tumor antigen
|
|
WO2017186928A1
(en)
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
|
EP4477662A3
(en)
|
2016-05-04 |
2025-03-19 |
CureVac SE |
Nucleic acid molecules and uses thereof
|
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
|
KR102469450B1
(ko)
|
2016-05-18 |
2022-11-22 |
모더나티엑스, 인크. |
인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
|
|
WO2017201342A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
EP3468613A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybrid carriers for nucleic acid cargo
|
|
AU2017286606A1
(en)
|
2016-06-14 |
2018-12-13 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US11279923B2
(en)
|
2016-11-28 |
2022-03-22 |
Curevac Ag |
Method for purifying RNA
|
|
BR112019010486A2
(pt)
|
2016-11-28 |
2019-09-10 |
Napajen Pharma Inc |
sirna quimicamente modificado
|
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
|
MA50335A
(fr)
|
2016-12-08 |
2020-08-19 |
Modernatx Inc |
Vaccins à acide nucléique contre des virus respiratoires
|
|
WO2018104538A1
(en)
*
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rna for treatment or prophylaxis of a liver disease
|
|
US11542490B2
(en)
|
2016-12-08 |
2023-01-03 |
CureVac SE |
RNAs for wound healing
|
|
EP3558354A1
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Lassa virus vaccine
|
|
EP3558356A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Mers coronavirus vaccine
|
|
EP3558355A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Henipavirus vaccine
|
|
US11241490B2
(en)
|
2017-01-11 |
2022-02-08 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified RNA for inducing an immune response against zika virus
|
|
AU2018234692B2
(en)
|
2017-03-15 |
2022-06-02 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
US20200030432A1
(en)
|
2017-03-17 |
2020-01-30 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
US11739335B2
(en)
|
2017-03-24 |
2023-08-29 |
CureVac SE |
Nucleic acids encoding CRISPR-associated proteins and uses thereof
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
EP3618859A4
(en)
|
2017-04-27 |
2021-05-05 |
Vanderbilt University |
HEPATITIS C VIRUS GENE SEQUENCES AND METHODS OF USE
|
|
US11820728B2
(en)
|
2017-04-28 |
2023-11-21 |
Acuitas Therapeutics, Inc. |
Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2018211038A1
(en)
|
2017-05-17 |
2018-11-22 |
Curevac Ag |
Method for determining at least one quality parameter of an rna sample
|
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
US10988754B2
(en)
|
2017-07-04 |
2021-04-27 |
Cure Vac AG |
Nucleic acid molecules
|
|
EP3668833A1
(en)
|
2017-08-16 |
2020-06-24 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
WO2019036000A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
US20200362382A1
(en)
|
2017-08-18 |
2020-11-19 |
Modernatx, Inc. |
Methods of preparing modified rna
|
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
JP2021502079A
(ja)
|
2017-11-08 |
2021-01-28 |
キュアバック アーゲー |
RNA配列の適合(Adaptation)
|
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
|
WO2019122371A1
(en)
|
2017-12-21 |
2019-06-27 |
Curevac Ag |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
|
WO2019193183A2
(en)
*
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
EP4227319B1
(en)
|
2018-04-17 |
2025-11-26 |
CureVac SE |
Novel rsv rna molecules and compositions for vaccination
|
|
IL279759B1
(en)
|
2018-06-28 |
2025-10-01 |
Tesla Automation GmbH |
Bioreactor for in vitro RNA transcription
|
|
US12263248B2
(en)
|
2018-09-19 |
2025-04-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EP3852911B1
(en)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
WO2020097002A1
(en)
*
|
2018-11-05 |
2020-05-14 |
The University Of North Carolina At Chapel Hill |
Optimized fig4 genes and expression cassettes and their use
|
|
SG11202106666UA
(en)
|
2018-12-21 |
2021-07-29 |
Curevac Ag |
Methods for rna analysis
|
|
WO2020160430A1
(en)
|
2019-01-31 |
2020-08-06 |
Modernatx, Inc. |
Vortex mixers and associated methods, systems, and apparatuses thereof
|
|
BR112021014845A2
(pt)
|
2019-01-31 |
2021-11-03 |
Modernatx Inc |
Métodos de preparação de nanopartículas lipídicas
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
US20230000908A1
(en)
*
|
2019-09-11 |
2023-01-05 |
Ohio State Innovation Foundation |
Engineered cells and uses thereof
|
|
JP2023511633A
(ja)
|
2020-01-28 |
2023-03-20 |
モデルナティエックス インコーポレイテッド |
コロナウイルスrnaワクチン
|
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
BR112022015565A2
(pt)
|
2020-02-07 |
2022-09-27 |
Modernatx Inc |
Vacinas de domínio de mrna para sars-cov-2
|
|
TW202204622A
(zh)
|
2020-04-09 |
2022-02-01 |
大陸商蘇州艾博生物科技有限公司 |
針對冠狀病毒之核酸疫苗
|
|
CN117003658B
(zh)
|
2020-04-09 |
2025-10-14 |
苏州艾博生物科技有限公司 |
脂质纳米颗粒组合物
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
CA3182994A1
(en)
|
2020-06-30 |
2022-01-06 |
Bo YING |
Lipid compounds and lipid nanoparticle compositions
|
|
MX2023000614A
(es)
|
2020-07-16 |
2023-02-13 |
Acuitas Therapeutics Inc |
Lipidos cationicos para usarse en nanoparticulas lipidicas.
|
|
JP2023537887A
(ja)
|
2020-08-20 |
2023-09-06 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
WO2022047325A1
(en)
*
|
2020-08-31 |
2022-03-03 |
The Trustees Of Columbia University In The City Of New York |
Targeting of tgm4 to treat prostate cancer
|
|
WO2022067010A1
(en)
|
2020-09-25 |
2022-03-31 |
Modernatx, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
MX2023007574A
(es)
|
2020-12-22 |
2023-09-29 |
CureVac SE |
"vacuna de arn contra variantes de sars-cov-2.
|
|
US12329811B2
(en)
|
2021-01-11 |
2025-06-17 |
Modernatx, Inc. |
Seasonal RNA influenza virus vaccines
|
|
CN116615472A
(zh)
|
2021-01-14 |
2023-08-18 |
苏州艾博生物科技有限公司 |
聚合物缀合的脂质化合物和脂质纳米颗粒组合物
|
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
AU2022207495A1
(en)
|
2021-01-15 |
2023-08-03 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
EP4277655A1
(en)
|
2021-01-15 |
2023-11-22 |
ModernaTX, Inc. |
Variant strain-based coronavirus vaccines
|
|
CN114908089B
(zh)
*
|
2021-02-08 |
2024-03-15 |
上海细胞治疗集团有限公司 |
3’utr的构建方法和应用
|
|
US20240299531A1
(en)
|
2021-03-15 |
2024-09-12 |
Moderna TX, Inc |
Therapeutic use of sars-cov-2 mrna domain vaccines
|
|
WO2022221335A1
(en)
|
2021-04-13 |
2022-10-20 |
Modernatx, Inc. |
Respiratory virus combination vaccines
|
|
US20240226277A1
(en)
|
2021-04-14 |
2024-07-11 |
ModernaTX. Inc. |
Influenza-coronavirus combination vaccines
|
|
WO2022245888A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Seasonal flu rna vaccines and methods of use
|
|
KR20240013087A
(ko)
|
2021-05-24 |
2024-01-30 |
쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 |
지질 화합물 및 지질 나노입자 조성물
|
|
IL309408A
(en)
|
2021-06-18 |
2024-02-01 |
Sanofi Sa |
Multivalent flu vaccines
|
|
AU2021461416A1
(en)
|
2021-08-24 |
2024-02-22 |
BioNTech SE |
In vitro transcription technologies
|
|
EP4402123A1
(en)
|
2021-09-14 |
2024-07-24 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and methods of use thereof
|
|
EP4402121A1
(en)
|
2021-09-14 |
2024-07-24 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
AU2022358824A1
(en)
|
2021-10-08 |
2024-04-11 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
KR20240090727A
(ko)
|
2021-10-22 |
2024-06-21 |
세일 바이오메디슨스, 인크. |
Mrna 백신 조성물
|
|
JP2024542085A
(ja)
|
2021-11-05 |
2024-11-13 |
サノフイ |
呼吸器合胞体ウイルスrnaワクチン
|
|
WO2023092069A1
(en)
|
2021-11-18 |
2023-05-25 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines and methods of use
|
|
AU2022398450A1
(en)
|
2021-11-23 |
2024-06-06 |
Sail Biomedicines, Inc. |
A bacteria-derived lipid composition and use thereof
|
|
US20230310571A1
(en)
|
2021-11-30 |
2023-10-05 |
Sanofi Pasteur Inc. |
Human metapneumovirus vaccines
|
|
JP2024545152A
(ja)
|
2021-12-08 |
2024-12-05 |
モデルナティエックス インコーポレイテッド |
単純ヘルペスウイルスmRNAワクチン
|
|
IL313486A
(en)
|
2021-12-16 |
2024-08-01 |
Acuitas Therapeutics Inc |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023111262A1
(en)
|
2021-12-17 |
2023-06-22 |
Sanofi |
Lyme disease rna vaccine
|
|
JP2025500373A
(ja)
|
2021-12-20 |
2025-01-09 |
セイル バイオメディシンズ インコーポレイテッド |
Mrna治療用組成物
|
|
US20250108007A1
(en)
|
2021-12-23 |
2025-04-03 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compound and lipid nanoparticle composition
|
|
EP4452928A1
(en)
|
2021-12-23 |
2024-10-30 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Man Inc |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
WO2023196914A1
(en)
|
2022-04-08 |
2023-10-12 |
Modernatx, Inc. |
Influenza nucleic acid compositions and uses thereof
|
|
WO2023230481A1
(en)
|
2022-05-24 |
2023-11-30 |
Modernatx, Inc. |
Orthopoxvirus vaccines
|
|
EP4554617A1
(en)
|
2022-07-13 |
2025-05-21 |
ModernaTX, Inc. |
Norovirus mrna vaccines
|
|
WO2024037578A1
(en)
|
2022-08-18 |
2024-02-22 |
Suzhou Abogen Biosciences Co., Ltd. |
Composition of lipid nanoparticles
|
|
CN120813372A
(zh)
|
2022-08-22 |
2025-10-17 |
促进军事医学的亨利·M·杰克逊基金会公司 |
针对冠状病毒的疫苗
|
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
|
EP4612300A1
(en)
|
2022-11-04 |
2025-09-10 |
Sanofi Pasteur Inc. |
Methods for messenger rna tailing
|
|
CN120152987A
(zh)
|
2022-11-04 |
2025-06-13 |
赛诺菲巴斯德有限公司 |
呼吸道合胞病毒rna疫苗接种
|
|
JP2025537750A
(ja)
|
2022-11-10 |
2025-11-20 |
セイル バイオメディシンズ インコーポレイテッド |
脂質ナノ粒子または脂質再構成天然メッセンジャーパックを含むrna組成物
|
|
WO2024126847A1
(en)
|
2022-12-15 |
2024-06-20 |
Sanofi |
Mrna recombinant capping enzymes
|
|
AU2023394992A1
(en)
|
2022-12-15 |
2025-07-31 |
Sanofi Pasteur Inc. |
Mrna encoding influenza virus-like particle
|
|
EP4638772A2
(en)
|
2022-12-23 |
2025-10-29 |
Sanofi Pasteur Inc. |
Optimized tailing of messenger rna
|
|
AU2024212425A1
(en)
|
2023-01-27 |
2025-08-07 |
Sail Biomedicines, Inc. |
A modified lipid composition and uses thereof
|
|
EP4658306A1
(en)
|
2023-01-30 |
2025-12-10 |
ModernaTX, Inc. |
Epstein-barr virus mrna vaccines
|
|
AR132053A1
(es)
|
2023-03-02 |
2025-05-21 |
Sanofi Pasteur |
Composiciones para su uso en el tratamiento de clamidia
|
|
CN120858173A
(zh)
|
2023-03-07 |
2025-10-28 |
赛诺菲巴斯德有限公司 |
用kp34聚合酶制造信使rna
|
|
WO2024192277A2
(en)
|
2023-03-15 |
2024-09-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
AU2024236558A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
WO2024215721A1
(en)
|
2023-04-10 |
2024-10-17 |
Modernatx, Inc. |
Lyme disease vaccines
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024231727A1
(en)
|
2023-05-05 |
2024-11-14 |
Sanofi |
Compositions for use in treatment of acne
|
|
AR132662A1
(es)
|
2023-05-10 |
2025-07-16 |
Sanofi Sa |
Combinación de vacunas respiratorias de arnm
|
|
WO2024254552A1
(en)
|
2023-06-08 |
2024-12-12 |
Modernatx, Inc. |
Stabilized flavivirus vaccines
|
|
WO2024263826A1
(en)
|
2023-06-22 |
2024-12-26 |
Modernatx, Inc. |
Sars-cov-2 t cell vaccines
|
|
WO2025003760A1
(en)
|
2023-06-28 |
2025-01-02 |
Sanofi |
Sterol analogs in lipid nanoparticle formulations
|
|
WO2025019352A2
(en)
|
2023-07-14 |
2025-01-23 |
Modernatx, Inc. |
Mers-cov mrna vaccines
|
|
WO2025017151A1
(en)
|
2023-07-18 |
2025-01-23 |
Sanofi |
Stable poly(a)-encoding messenger rna templates
|
|
AR133317A1
(es)
|
2023-07-19 |
2025-09-17 |
Sanofi Sa |
Constructos antigénicos de porphyromonas gingivalis
|
|
WO2025029700A1
(en)
|
2023-07-28 |
2025-02-06 |
Modernatx, Inc. |
Vlp enteroviral vaccines
|
|
WO2025034612A1
(en)
|
2023-08-04 |
2025-02-13 |
Modernatx, Inc. |
Varicella-zoster virus mrna vaccine
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
TW202527960A
(zh)
|
2023-09-06 |
2025-07-16 |
美商賽諾菲巴斯德公司 |
經修飾b型流感血球凝集素多肽及核酸及其用途
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025134071A1
(en)
|
2023-12-22 |
2025-06-26 |
Sanofi |
Malic and glutaric acid based ionizable lipids
|
|
WO2025141521A1
(en)
|
2023-12-29 |
2025-07-03 |
Sanofi |
Lipids having dendritic moieties
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025210592A1
(en)
|
2024-04-05 |
2025-10-09 |
Sanofi Pasteur Inc. |
Muscle cell lnp-mrna quality control assays
|
|
WO2025226656A1
(en)
|
2024-04-23 |
2025-10-30 |
Modernatx, Inc. |
Hepatitis b virus mrna vaccines
|